What is ProSciento?
ProSciento, formerly Profil Institute for Clinical Research, Inc., operates as a clinical research organization with a dedicated focus on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD/NASH). The company provides a comprehensive suite of services essential for clinical development, including regulatory affairs, scientific consultation, data management, statistical analysis, monitoring, quality assurance, and patient recruitment. Its expertise is crucial for advancing therapeutic research in these prevalent health areas.
How much funding has ProSciento raised?
ProSciento has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in ProSciento
PPP
Public-Private Partnership
What's next for ProSciento?
With the backing indicated by its major enterprise-level funding, ProSciento is poised for accelerated growth and enhanced service delivery. The capital infusion is expected to fuel advancements in its clinical research capabilities, potentially expanding its operational footprint and deepening its impact on the development of treatments for metabolic disorders. This strategic financing will likely support further innovation in clinical trial management and data analytics, reinforcing ProSciento's position as a key player in the CRO sector.
See full ProSciento company page
